heart ecg arrhythmia The FDA has approved the Prior Approval Supplement for Bretylium Tosylate Injection, allowing ANI Pharmaceuticals to market the once discontinued antiarrhythmic agent. The Food ...
RSD1235 is a novel, frequency-dependent sodium and early-activating potassium-channel blocker under joint development by Cardiome (Vancouver, Canada) and its partner, Astellas Pharma US (Deerfield, ...
The DFT is defined as the lowest delivered energy that will convert VF to a supraventricular rhythm. An increase in DFT may lead to failure of device therapy, and as a result may have severe ...
Atrial fibrillation is the most common type of cardiac arrhythmia, and is a common cause of stroke and heart failure. Currently, there is a major unmet need for drugs that are capable of successfully ...
Background: Of the antiarrhythmic agents currently marketed in Canada, 5 are commonly used to treat atrial fibrillation (AF). The impact of contraindications, warnings and precautions for the use of ...
The batch was distributed between August 14, 2018 and September 5, 2018. Nexterone is a prescription antiarrhythmic agent indicated for initiation of treatment and prophylaxis of frequently recurring ...
Short-term antiarrhythmic drug therapy with flecainide can prevent most episodes of recurrent atrial fibrillation (AF) in patients who have undergone electrical cardioversion. Despite being not as ...
The American Heart Association (AHA) has released a new scientific statement for managing clinically significant drug-drug interactions in patients who are prescribed statins and other agents used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback